Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
October 15, 2020 04:56 PM EDT
R&D

Gilead feels the heat as close al­ly Gala­pa­gos re­ports a big set­back on one of their top ex­per­i­men­tal drugs

John Carroll

Editor & Founder

The bad news keeps stack­ing up at Gala­pa­gos — which quite like­ly just lost con­trol of a bil­lion-dol­lar deal — and by ex­ten­sion their close part­ners at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times